Cargando…

Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial

PURPOSE: To analyze the safety and efficacy of orally administered metronomic capecitabine plus pyrotinib in HER2 positive metastatic breast cancer (MBC) patients, we conducted a prospective phase II study with a single-arm design. METHODS: HER2 positive patients received oral metronomic capecitabin...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Maiyue, Liu, Jiaxuan, Wang, Zijing, Ma, Fei, Wang, Jiayu, Zhang, Pin, Li, Qing, Yuan, Peng, Luo, Yang, Fan, Ying, Mo, Hongnan, Lan, Bo, Li, Qiao, Xu, Binghe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520922/ https://www.ncbi.nlm.nih.gov/pubmed/37742492 http://dx.doi.org/10.1016/j.breast.2023.103581

Ejemplares similares

A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer
por: Chai, Yue, et al.
Publicado: (2023)

Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2023)

Current Research Status of Metronomic Chemotherapy in Combination Treatment of Breast Cancer
por: Liu, Jiaxuan, et al.
Publicado: (2022)

Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies
por: Guan, Xiuwen, et al.
Publicado: (2023)

Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial
por: Wang, Zijing, et al.
Publicado: (2021)

Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage
por: Guan, Xiuwen, et al.
Publicado: (2020)

Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study
por: Jiang, Mingxia, et al.
Publicado: (2023)

Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage
por: Bao, Yuwen, et al.
Publicado: (2022)

Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A study of the National Cancer Center, China
por: Li, Yiqun, et al.
Publicado: (2021)

Comparison of capecitabine-based regimens with platinum-based regimens in Chinese triple-negative breast cancer patients with liver metastasis
por: Chen, Yimeng, et al.
Publicado: (2021)

Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study
por: Xie, Yizhao, et al.
Publicado: (2021)

Metronomic chemotherapy with capecitabine for metastatic colorectal cancer in very elderly patients
por: Jung, Yun Hwa, et al.
Publicado: (2017)

In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China
por: Li, Yiqun, et al.
Publicado: (2022)

Improved survival in patients with isolated liver metastasis at initial diagnosis with surgery at primary and metastatic sites: A population‐based study in patients with breast cancer
por: Chai, Yue, et al.
Publicado: (2023)

Durable Effect of Pyrotinib and Metronomic Vinorelbine in HER2-Positive Breast Cancer With Leptomeningeal Disease: A Case Report and Literature Review
por: Chi, Yajing, et al.
Publicado: (2022)

Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population
por: Mo, Hongnan, et al.
Publicado: (2022)

Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer
por: Lin, Shaoyan, et al.
Publicado: (2019)

Risk Factors and Survival of Patients With Liver Metastases at Initial Metastatic Breast Cancer Diagnosis in Han Population
por: Lin, Shaoyan, et al.
Publicado: (2021)

Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
por: Li, Yi, et al.
Publicado: (2021)

Durable effect of pyrotinib plus capecitabine in HER-2+ breast cancer patient undergoing peritoneal dialysis: A case report and literature review
por: Jin, Xiangting, et al.
Publicado: (2022)

Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial
por: Cao, Jun, et al.
Publicado: (2023)

Metronomic capecitabine as maintenance treatment after first line induction with XELOX for metastatic colorectal cancer patients
por: Geng, Rui, et al.
Publicado: (2020)

Clinicopathological characteristics and survival outcomes in patients with synchronous lung metastases upon initial metastatic breast cancer diagnosis in Han population
por: Lin, Shaoyan, et al.
Publicado: (2021)

Pyrotinib for HER2-positive metastatic breast cancer: a systematic review and meta-analysis
por: Hu, Wenyu, et al.
Publicado: (2023)

Pyrotinib Improves Survival in Previously Treated HER2-Positive Metastatic Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Case Report: Effective Treatment With Pyrotinib and Capecitabine in a Heavily Pretreated Locally Advanced Breast Cancer Harboring Both HER2 Overexpression and Mutant
por: Gao, Zhichao, et al.
Publicado: (2021)

Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China
por: Li, Yiqun, et al.
Publicado: (2020)

Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma
por: Al-Sukhun, Sana, et al.
Publicado: (2023)

Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations
por: Tian, Hao, et al.
Publicado: (2023)

Sustained Clinical Benefit of Pyrotinib Combined with Capecitabine Rescue Therapy After Trastuzumab Resistance in HER2-Positive Advanced Gastric Cancer: A Case Report
por: Li, Xin, et al.
Publicado: (2021)

Radiosensitization of HER2-positive esophageal cancer cells by pyrotinib
por: Lian, Xiangyao, et al.
Publicado: (2020)

Pyrotinib for Elderly Patients with Advanced HER2-Positive Breast Cancer
por: Li, Yan, et al.
Publicado: (2022)

Metronomic capecitabine inhibits liver transplant rejection in rats by triggering recipients’ T cell ferroptosis
por: Wang, Hao, et al.
Publicado: (2023)

P110α inhibitor alpelisib exhibits a synergistic effect with pyrotinib and reverses pyrotinib resistant in HER2+ breast cancer
por: Chen, Hao, et al.
Publicado: (2023)

Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study
por: Berruti, Alfredo, et al.
Publicado: (2014)

The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer
por: Wang, Chaokun, et al.
Publicado: (2021)

The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer
por: Wang, Yukun, et al.
Publicado: (2021)

Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial
por: Ma, Fei, et al.
Publicado: (2023)

Pyrotinib as a therapeutic for HER2-positive breast cancer
por: Kioutchoukova, Ivelina, et al.
Publicado: (2023)

The efficacy and safety of using pyrotinib combined with capecitabine as neoadjuvant therapy in elderly patients with HER2-positive breast cancer: a single-arm prospective clinical trial
por: Wang, Wei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ljdne66h46554vu24qjgkag8t0